T. Rowe Price Associates
OTLK icon

T. Rowe Price Associates’s Outlook Therapeutics OTLK Stock Holding History

T. Rowe Price Associates’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,668
Closed -$14K – 2971
2023
Q4 		$14K Hold
1,668
– – ﹤0.01% 2882
2023
Q3 		$8K Buy
1,668
+207
+14% +$4.58K ﹤0.01% 2872
2023
Q2 		$51K Hold
1,461
– – ﹤0.01% 2800
2023
Q1 		$32K Buy
1,461
+499
+52% +$11.2K ﹤0.01% 2826
2022
Q4 		$21K Buy
962
+132
+16% +$2.87K ﹤0.01% 2874
2022
Q3 		$21K Buy
830
+270
+48% +$6.28K ﹤0.01% 2911
2022
Q2 		$11K Buy
+560
New +$16.1K ﹤0.01% 2943

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

T. Rowe Price Associates's OTLK Position: Q1 2024 in Review

T. Rowe Price Associates sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 1,668 shares — an estimated $14K sold.

T. Rowe Price Associates first reported a position in OTLK in Q2 2022 and held it in 7 quarters. The position peaked at $51K in Q2 2023. 56 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

  • T. Rowe Price Associates reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,668 Outlook Therapeutics shares in Q1 2024, an estimated $14K.
  • T. Rowe Price Associates first reported a position in Outlook Therapeutics in Q2 2022 and held it in 7 quarters.
  • T. Rowe Price Associates's Outlook Therapeutics position peaked at $51K in Q2 2023.
  • 56 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.